BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28
• 29
• 30
• 31

• 

  Drug Development

  In Step Forward, FDA Approves First Bispecific Antibody for AMD and DME

  The FDA’s decision is based on positive results from several Phase III studies, including the TENAYA and LUCERNE clinical trials.

  January 31, 2022

   · 

  2 min read

   · 

  Vanessa Doctor, RN
• 

  Career Advice

  Effectively Using and Interpreting Body Language During Interview

  The use of body language during interview can ensure a good impression. Kinesics includes the use of posture, facial expression, movement, and gestures to communicate nonverbally.

  January 31, 2022

   · 

  6 min read

   · 

  Karen Walpole
• 

  Drug Development

  Moderna’s Spikevax Scores Full FDA Approval while Omicron BA.2 Picture Emerges

  News that a subvariant of the Omicron variant has appeared in the U.S. and parts of Europe doesn’t seem like good news. The latest data suggest it’s 1.5 times more transmissible than the original Omicron variant, but not necessarily deadlier.

  January 31, 2022

   · 

  6 min read

   · 

  Mark Terry
• 

  Business

  Biogen Departure Train Chugs on as Two Board Members Exit

  One week after Johnna Rossell departed Biogen for Enzyvant, Biogen announced two more members of its board are leaving.

  January 31, 2022

   · 

  2 min read

   · 

  Alex Keown
• 

  Business

  Pfizer Abandons Ionis’ Cardiovascular and High Triglyceride Program

  The decision came after the Phase IIb study results demonstrating a statistically significant decrease in non-HDL-C and statistically significant reductions in triglycerides and ANGPTL3.

  January 31, 2022

   · 

  3 min read

   · 

  Mark Terry
• 

  Drug Development

  Potential New Obesity Drug Heads to Phase II Trials

  Altimmune announced Monday that the U.S. Food and Drug Administration (FDA) has approved a Phase II clinical trial for investigational new obesity drug pemvidutide.

  January 31, 2022

   · 

  2 min read

   · 

  Hannah Chudleigh
• 

  Drug Development

  The Epidemic of Obesity and its Impact on the Immune System

  You are what you eat, and your defense system notices that.

  January 31, 2022

   · 

  9 min read

   · 

  Ignacio Guerrero-Ros, Ph.D. (Guest Contributor)
• 

  Drug Development

  Positive Phase III Data Lifts Madrigal, Hopes for an Effective NASH Treatment

  Shares of Madrigal Pharmaceuticals went up in premarket trading after the company announced positive topline data from its Phase III assessment of resmetirom in non-alcoholic fatty liver disease.

  January 31, 2022

   · 

  3 min read

   · 

  Alex Keown
• 

  Drug Development

  Scientists Link Alzheimer’s Disease with Immune System Dysfunction

  Scientists believe that, perhaps, Alzheimer’s disease is a cause of not just beta-amyloid accumulation but, digging more deeply, immune system dysfunction.

  January 31, 2022

   · 

  2 min read

   · 

  Vanessa Doctor, RN
• 

  Business

  Vancouver Startup Nets $40M to Marry the Power of Cryo-EM and AI

  The union has one primary goal – speed up discovery and development to get effective drugs to patients sooner.

  January 31, 2022

   · 

  2 min read

   · 

  Kate Goodwin